Sign up to save your podcasts
Or
Share PubReading [145] - CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities - L. Fonkoua, S. Kenderian et al
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
PubReading [145] - CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities - L. Fonkoua, S. Kenderian et al
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable outcomes in individuals with hematological malignancies, but its success has been hindered by barriers intrinsic to the tumor microenvironment (TME), particularly for solid tumors, where it has yet to make its mark. In this article, we provide an updated review and future perspectives on features of the TME that represent barriers to CART cell therapy efficacy, including competition for metabolic fuels, physical barriers to infiltration, and immunosuppressive factors. We then discuss novel and promising strategies to overcome these obstacles that are in preclinical development or under clinical investigation.
doi.org/10.1016/j.omto.2022.03.009 - 2022
View all episodes
By Mando MouradChimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable outcomes in individuals with hematological malignancies, but its success has been hindered by barriers intrinsic to the tumor microenvironment (TME), particularly for solid tumors, where it has yet to make its mark. In this article, we provide an updated review and future perspectives on features of the TME that represent barriers to CART cell therapy efficacy, including competition for metabolic fuels, physical barriers to infiltration, and immunosuppressive factors. We then discuss novel and promising strategies to overcome these obstacles that are in preclinical development or under clinical investigation.
doi.org/10.1016/j.omto.2022.03.009 - 2022
More shows like PubReading
View all
ESGfitness
33 Listeners